Valuation dashboard for Context Therapeutics Inc. (CNTX) with P/E N/A, P/B 0.91, EV/EBITDA 0.23 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $0.38, CNTX has negative trailing earnings (P/E not meaningful) and an ROE of -82.06%. Market capitalisation stands at $35M.
Balance sheet quality for CNTX: current ratio of 8.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.91 |
| EV / EBITDA | 0.23 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.67 |
| vs Current Price | +76.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CNTX | Context Therapeutics Inc. | $35M | 0.91 | -82.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.38 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -82.06% |
| Return on Invested Capital | -126.84% |
| Return on Assets | -99.62% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLNN · CNTB · IFRX · IMA · KLRS · MGNX · ORMP
Explore sector: Healthcare · Biotechnology
More sections of CNTX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks